Tempest Therapeutics, Inc.: Form 10-Q for the period ended Mar 31, 2015
Filed with the SEC on May 11, 2015 and accepted by EDGAR at May 11, 2015, 16:12 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2015-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2015-01-01 to 2015-03-31 | $15.0k | us-gaap:Revenues |
| Cost of revenue | 3 months2015-01-01 to 2015-03-31 | $35.0k | us-gaap:CostOfRevenue |
| Research and development | 3 months2015-01-01 to 2015-03-31 | $5.7m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2015-01-01 to 2015-03-31 | $11.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2015-01-01 to 2015-03-31 | −$16.8m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2015-01-01 to 2015-03-31 | −$17.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2015-01-01 to 2015-03-31 | −$0.65 | us-gaap:EarningsPerShareBasicAndDiluted |
| Capital expenditure | 3 months2015-01-01 to 2015-03-31 | $389.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2015-03-31 | $134.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2015-03-31 | $171.3m | us-gaap:AssetsCurrent |
| Total assets | At period end2015-03-31 | $175.8m | us-gaap:Assets |
| Current liabilities | At period end2015-03-31 | $6.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2015-03-31 | $6.7m | us-gaap:Liabilities |
| Shareholders' equity | At period end2015-03-31 | $169.1m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001104659-15-036822. Last ingested by Listed: Nov 15, 2026, 00:20 ET. Listed shows no prices and gives no investment advice.